Esophageal Squamous Cell Carcinoma
327
85
110
72
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
11 trials with published results (3%)
Research Maturity
72 completed trials (22% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
4.0%
13 terminated out of 327 trials
84.7%
-1.8% vs benchmark
9%
30 trials in Phase 3/4
15%
11 of 72 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 72 completed trials
Clinical Trials (327)
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors